KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash from Financing Activities (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Cash from Financing Activities for 17 consecutive years, with -$1.4 billion as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 24.93% to -$1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.3 billion through Dec 2025, down 16.75% year-over-year, with the annual reading at -$6.3 billion for FY2025, 16.75% down from the prior year.
  • Cash from Financing Activities hit -$1.4 billion in Q4 2025 for Abbott Laboratories, up from -$1.8 billion in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of -$791.0 million in Q2 2024 to a low of -$3.8 billion in Q1 2022.
  • Historically, Cash from Financing Activities has averaged -$1.6 billion across 5 years, with a median of -$1.4 billion in 2022.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 295.35% in 2022 and later surged 63.12% in 2023.
  • Year by year, Cash from Financing Activities stood at -$1.9 billion in 2021, then increased by 22.75% to -$1.5 billion in 2022, then plummeted by 40.84% to -$2.1 billion in 2023, then rose by 9.31% to -$1.9 billion in 2024, then increased by 24.93% to -$1.4 billion in 2025.
  • Business Quant data shows Cash from Financing Activities for ABT at -$1.4 billion in Q4 2025, -$1.8 billion in Q3 2025, and -$1.1 billion in Q2 2025.